Nonsurgical treatment of Dupuytren's contracture: 1-year US post-marketing safety data for collagenase clostridium histolyticum

Hand

Volumn 7, Issue 2, 2012, Pages 143-146

  Peimer, C A ^a   McGoldrick, C A ^c   Fiore, G J ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b SSI Strategy   (United States)

^c Auxilium Pharmaceuticals   (United States)

Author keywords

Clinical adverse event; Collagenase clostridium histolyticum; Dupuytren's contracture

Indexed keywords

EID: 84861197199     PISSN: 15589447     EISSN: 15589455     Source Type: Journal    
DOI: 10.1007/s11552-012-9407-3     Document Type: Article

References (14)

1. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003; 18: 57-60.
2. Auxilium Pharmaceuticals Inc. AAC briefing document for collagenase clostridium histolyicum. Malvern, PA: Auxilium Pharmaceuticals, Inc.; September 16, 2009.
3. Chen NC, Srinivasan RC, Shauver MJ, Chung KC. A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture. Hand. 2011; 6: 250-5.
4. Chigot PL. Foreword: Baron Dupuytren. In: Hueston JT, Tubiana R, editors. Dupuytren's disease. New York: Grune & Stratton; 1974. ix-x.
5. Cooper A. A treatise on dislocations and fractures of the joints. London: Churchill; 1842.
6. Denkler K. Surgical complications associated with fasciectomy for Dupuytren's disease: a 20-year review of the English literature. J Plast Surg. 2010; 10: 116-33.
7. Desai SS, Hentz VR. Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opin Biol Ther. 2010; 10: 1395-404.
8. Elliot D. The early history of contracture of the palmar fascia. Part 2: the revolution in Paris: Guillaume Dupuytren: Dupuytren's disease. J Hand Surg Eur. 1988; 13: 371-8.
9. French MF, Mookhtiar KA, van Wart HE. Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry. 1987; 26: 681-7.
10. Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010; 35A: 2027-2083. e1.
11. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009; 361: 968-79.
12. Hutchison RL, Rayan GM. Astley Cooper: his life and surgical contributions. J Hand Surg Am. 2011; 36: 316-20.
13. Starkweather KD, Lattuga S, Hurst LC, Badalamente MA, Guilak F, Sampson SP, et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am. 1996; 21: 490-5.
14. Zhang AY, Curtin CM, Hentz VR. Flexor tendon rupture after collagenase injection for Dupuytren contracture: case report. J Hand Surg Am. 2011; 36: 1323-5.